About us

Driven by passion and curiosity for science, we aim for some of the most urgent but also most complex challenges in drug development.

Philipp Bürling

Philipp Bürling, MBA

CEO
Learn more
Dr. Antje Willuweit

Dr. Antje Willuweit

Director Preclinical Development
Learn more
Dr. Dagmar Jürgens

Dr. Dagmar Jürgens

Director Clinical Development
Learn more
Dr. Knut Adermann

Dr. Knut Adermann

Director CMC
Learn more
Dr. Gunther Kauselmann

Dr. Gunther Kauselmann

Director Quality Management and Regulatory Compliance
Learn more
Prof. Dr. Detlev Riesner

Prof. em. Dr. Dr. h.c. Detlev Riesner

Chairman
Learn more
Prof. Dr. Dieter Willbold

Prof. Dr. Dieter Willbold

Dr. Johannes Schmiegel

Dr. Johannes Schmiegel

Prof. Dr. Jörg Breitkreutz

Prof. Dr. Jörg Breitkreutz

Learn more
Dr. Waleed Danho

Dr. Waleed Danho

Learn more
Prof. Dr. med. Gereon R. Fink

Prof. Dr. med. Gereon R. Fink

Learn more
Prof. Dr. med. Oliver Peters

Prof. Dr. med. Oliver Peters

Learn more
Prof. Dr. Holger Stark

Prof. Dr. Holger Stark

Learn more
Prof. Dr. med. Inga Zerr

Prof. Dr. med. Inga Zerr

Learn more

Our team consists of highly skilled and specialized scientists with different backgrounds. Scientific excellence is both a goal and a demand on ourselves.

Prof. Dr. Dieter Willbold

"Decades of research have gone into a unique treat­ment concept for neuro­degener­ative diseases. Priavoid continues to translate this concept into the development of efficient and safe drugs."

Prof. Dr. Dieter Willbold, Co-Founder

Prof. Dr. Dieter Willbold

Forschungszentrum Jülich / Sascha Kreklau